Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a...

Related Keywords

Canada ,United States ,Canadian ,Michaelj Mcelhaugh ,N Acetylgalactosamine Galnac ,Barinthus Bio ,Lisam Caperelli ,Clinical Development Milestones ,World Health Organization ,Securities Exchange ,Court Scheduling Order ,Arbutus Biopharma Corporation Nasdaq ,Biopharma Corporation ,Interim President ,Chief Executive Officer ,Liver Meeting ,Looking Statements ,Securities Act ,Securities Exchange Act ,Arbutu Annual Report ,Arbutu Quarterly Reports ,Investor Relations ,Markets ,